At BIO 2025, As Political Shifts Continue, Key Leaders Respond
In contrast to earlier conferences in 2025, experts interviewed as part of the BIO conference in Boston did not come to a consensus about lasting impacts of recent changes in US government policy.
BIO 2025: Speeding Up Development of Next-Generation Biologics
Matthew Stober and Campbell Bunce of Abzena talk about the CDMO’s role in accelerating the path of newer and more effective modalities to market.
Abu Dhabi Health Department's US Mission Yields Multiple Strategic Agreements
The department’s newly announced partnerships were part of a weeklong visit that included discussions held at BIO 2025.
BIO 2025: Building Relationships Amid a Rebrand
FUJIFILM representatives talked about the rebrand of the company’s life sciences businesses, partnerships with Regeneron and other companies, and the importance of having a presence at conferences like BIO 2025.
BIO 2025: CDMO Partnerships in the Biologics Field
Bartłomiej Czubek, director of Business Development at Mabion, discussed what’s working, and the challenges set forth by what isn’t working, in the relationships built within the present biologics CDMO market.
Patient-Driven Innovation and an Investigational tRNA-based Gene Therapy
Tevard Biosciences CEO Daniel Fischer discusses tackling Dravet syndrome with a scalable, mutation-targeted approach and building a mission-led company culture.
Ecolab Introduces New Bioprocessing Purification Resin at BIO 2025
The Purolite AP+50 affinity chromatography resin has a 50-micron bead size that offers dynamic binding capacity of the AP resin platform while providing durability for monoclonal antibody capture.
BIO 2025: Finding the Right Partner for Innovation
Korro Bio CEO and president Ram Aiyar, PhD, delves into his company’s partnership with Novo Nordisk as a means of reaching a larger patient population with new ideas and approaches.
BIO 2025: Considerations for Drug Development
BioPharm International® spoke with Robert Cornog, senior director, Product Development, at Quotient Sciences about how commercial manufacturing and tech transfer impact biopharmaceuticals at the development stage.
BIO 2025: New Perspectives on RNA Editing
Korro Bio CEO Ram Aiyar discusses his company’s platform that tunes the RNA editing process to target a wider range of rare diseases.
Funding in Early-Stage Biotech and the Promise of siRNA
PCI Pharma Services Introduces New Manufacturing Facility Ahead of BIO 2025
The facility is on the company’s Bedford, NH campus, where another existing building will be repurposed into a Development Center of Excellence.